Join Bio-Rad multiplex immunodetection experts for a webinar series that explores the many factors that go into the design and execution of successful xMAP multiplex immunoassays. Not only will we cover the technology and general how to’s, we’ll also delve into the why’s to give you a deeper understanding and get you on the right path for success. By the end of this series, you’ll be a multiplexing expert. Let’s do this!
Bio-Plex Multiplex Immunoassay Technology Overview and Setting Up to Run an Assay
Brett Houser, Bio-Plex Multiplex Immunoassay Product Manager, Protein Quantitation Group
Tuesday, March 20, 2018, 9 AM Pacific Daylight Time
Multiplex immunoassays continue to be an extremely powerful tool for protein detection and quantitation. Used consistently over many years and many applications, multiplex immunoassays have proven to be invaluable when broad screening of many analytes is needed. Additionally, this technique offers increased sensitivity, dynamic range, and quantitation limits over those of standard ELISA. Here we present a general overview and tips on setting up experiments to optimize your results.
Maximizing Your Mouse: Using the power of Bio-Plex to analyze mouse models of disease and treatment
Daniel Braunschweig, PhD, Proteomics Field Application Scientist Leader
March 19, 2019 10:00 AM Pacific time
Mouse models are widely used in biomedical research, though accurately identifying and measuring their relevant protein biomarkers remains a central challenge. This presentation will provide an overview of multiplexing technology for research using mouse samples and highlight the associated benefits to your drug discovery workflow.
Specific topics covered will include:
Using the Bio-Plex Pro Human Immunotherapy Panel to Elucidate Changes in T Cells after Treatment with Nivolumab
Larry Wong, PhD, Senior Scientist
May 19, 9:00 AM PST
Anti‑PD1 therapy has proven to be a potent treatment in the fight against hematologic cancers, as evidenced by commercially available, FDA‑approved anti‑PD1 antibodies currently used in patients. However, in solid tumors anti‑PD1 treatment has been less successful due to the complex composition of the tumor microenvironment. Additionally, cancers treated with a certain type of targeted therapy have been shown to upregulate other checkpoint receptors to continue their immune escape. A way to monitor these changes may help clinicians determine the appropriate course of action if a patient stops responding to their therapy. The Bio‑Plex Pro Human Immunotherapy Panel can be used to monitor changes in cytokine expression over the course of treatment. Observed changes in phenotype can be used to coordinate the appropriate follow‑up treatment. The panel includes cytokines found in cytokine release syndrome, a common and potentially deadly side effect of certain anticancer therapies.
The Role of Aberrant Cytokine Activity in the Host Immune Response to COVID-19
Featuring an Expert SARS-CoV-2 Panel
Session 1: June 10, 9:00 AM PT/18:00 PM CEST
Session 2: June 10, 7:00 PM PT/June 11, 10:00 AM SGT
In this webinar, we will be discussing early research and nascent hypotheses regarding the pathophysiology of SARS-CoV-2 induced COVID-19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.